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Abstract
Background: The objective was to describe the causes of initial and overall AIDS-defining disease
episodes among HIV patients in Singapore.
Methods: A retrospective observational cohort study was performed of all adult patients seen at
the national HIV referral center between 1985 and 2001. Data were extracted from the patients'
records by ten trained healthcare workers. AIDS-defining conditions were established using
predefined criteria.
Results: Among 1504 patients, 834 had experienced one or more AIDS-defining diseases. The
most frequent causes of the initial AIDS-defining episode were Pneumocystis carinii pneumonia
(35.7%), Mycobacterium tuberculosis (22.7%) and herpes simplex (7.4%). In total 1742 AIDS-defining
episodes occurred. The most frequent causes were Pneumocystis carinii pneumonia (25.1%),
Mycobacterium tuberculosis (16.2%) and cytomegalovirus retinitis (9.5%).
Conclusions: The most frequent causes of AIDS-defining illnesses in Singapore are similar to
those reported in the West, prior to the introduction of anti-retroviral therapy. Opportunistic
infections remain the most frequent AIDS-defining illnesses.
Background
Cohort studies have provided valuable information on
the clinical course of HIV infection in patients from
Europe [1-16], North America [3,17-21], South America
[22,23] and Africa [24-32]. The introduction of antiretro-
viral therapy has dramatically altered the incidence of
AIDS-defining illnesses in the West. In the EuroSIDA
study there have been substantial falls in the incidence
and total number of AIDS-defining episodes between
1994 and 1998 [10]. During this period the proportions
of reported AIDS-defining illnesses due to cytomegalovi-
rus retinitis and Mycobacterium avium have decreased from
9% to 2% and 8% to 3% respectively [10]. The proportion
due to non-Hodgkin's lymphoma has increased from 4%
to 16% [10]. Substantial decreases in the incidence of dis-
ease caused by cytomegalovirus, Pneumocystis carinii,
Mycobacterium avium and other opportunistic infections
have also been observed in the United States [20,21].
Published: 12 November 2004
BMC Infectious Diseases 2004, 4:47 doi:10.1186/1471-2334-4-47
Received: 10 August 2004
Accepted: 12 November 2004
This article is available from: http://www.biomedcentral.com/1471-2334/4/47
© 2004 Bellamy et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2004, 4:47 http://www.biomedcentral.com/1471-2334/4/47
Page 2 of 7
(page number not for citation purposes)
Relatively few data are available on the course of HIV
infection in Asian populations. In Bangkok between 1987
and 1993 the most frequent AIDS-defining diagnoses
were extrapulmonary tuberculosis (22.8%), Pneumocystis
carinii  pneumonia (7.0%) and cryptococcal meningitis
(10.9%) [33]. Little is known regarding whether the pat-
tern of HIV-related conditions has changed following the
introduction of antiretroviral therapy in Asia.
The Communicable Diseases Centre (CDC) in Singapore
is the national reference centre for adult patients with HIV
and AIDS and nationwide 94.9% of all Singaporean adult
residents, who have ever been diagnosed, have been
referred there. Underreporting of HIV does not occur as
reporting occurs automatically from the reference labora-
tory. Records have been kept since the first case was iden-
tified in Singapore in 1985. Therefore the Singapore HIV
Observational Cohort Study (SHOCS) contains almost
the entire country's HIV experience. Nucleoside analogues
have been available in Singapore since the early 1990s
and protease inhibitors and non-nucleoside reverse tran-
scriptase inhibitors since 1997. The usage of these drugs
has been increasing annually and during 2000 and 2001
approximately 70–80% of patients regularly attending
CDC were taking some form of anti-retroviral therapy.
Methods
The details of the SHOCS cohort have been described pre-
viously [34]. The study was approved by the Ethics Com-
mittee of Tan Tock Seng Hospital. Data were extracted
from the case notes of all Singaporean residents who were
seen at CDC on or before 31st December 2001, by ten
trained healthcare workers. Probable and confirmed crite-
ria were developed for the diagnosis of category C [34]
and category B (AIDS-related complex) conditions, based
on the 1993 guidelines of the United States' Centers for
Disease Control and Prevention [35].
All disease episodes were initially determined by the data
extractors and then checked by an infectious disease phy-
sician (RB). Diagnoses were not included if they did not
fulfill the specified criteria even if there was a strong clin-
ical suspicion of a particular condition. If there was insuf-
ficient evidence to satisfy the criteria for a specific
diagnosis, a more general diagnosis was assigned, for
example cerebral lesion (cause unknown) would be used
if there was insufficient evidence to support a diagnosis of
toxoplasmosis of the brain or primary cerebral
lymphoma.
Median CD4 counts were calculated based on the sample
taken nearest the time of diagnosis of the initial AIDS-
defining condition. CD4 counts from 893 patients were
used, as in 37 (4.0%) cases no suitable count was availa-
ble. Data were entered into a computer database (Micro-
soft Access™) and checked for errors and inconsistencies.
Statistical analyses were performed using Stata 7.0™. Each
new or recurrent AIDS-defining condition counted as one
event (i.e. a patient with three diagnoses would contribute
three events). An AIDS-defining condition was counted as
a separate additional event if it recurred six or more
months after the initial diagnosis or in the case of tuber-
culosis, six or more months after treatment completion.
To examine the effects of highly active anti-retroviral ther-
apy (HAART) on the proportions of AIDS-defining ill-
nesses due to each of the three most common infections
(Pneumocystis carinii pneumonia, Mycobacterium tuberculo-
sis  and cytomegalovirus retinitis), comparisons were
made between the pre-HAART era (1986 to 1995) and the
established HAART era (2000 to 2001) using χ2 tests.
Results
Among the 1504 patients infected with HIV who were
seen at CDC between 1985 and the end of 2001, 834
developed one or more AIDS-defining conditions. The
most frequent initial AIDS-defining disease episodes were
due to Pneumocystis carinii pneumonia (35.7% of total
diagnoses),  M. tuberculosis (22.7%), herpes simplex
(chronic mucocutaneous) (7.4%) and candidiasis
(esophageal or tracheobronchial) (6.9%) (table 1). The
median CD4 count at which the initial AIDS-defining
condition occurred was 27 (inter-quartile range 11 – 63).
The median CD4 count was higher for M. tuberculosis
infection (52, IQR = 18 – 110) and Kaposi's sarcoma
(46.5, IQR = 23.5 – 227.5) than for Pneumocystis carinii
pneumonia (16.5, IQR = 9 – 40), herpes simplex (25, IQR
= 9 – 63) and extrapulmonary cryptococcosis (13, IQR =
6.5 – 39) (table 1).
1742 AIDS-defining disease episodes were recorded. The
10 most frequent AIDS-defining conditions were all of
infectious etiology. There were 1658 first episodes of dis-
ease and 84 recurrences. The most frequent AIDS-defining
diseases were Pneumocystis carinii pneumonia (25.1% of
total diagnoses), M. tuberculosis (16.2%), cytomegalovirus
retinitis (9.5%), candidiasis (7.8%), chronic mucocutane-
ous herpes simplex (8.2%) and disseminated M. avium
(8.2%) (table 2). Several additional conditions could
have included undiagnosed AIDS-defining diseases. The
most common of these infections was pneumonia of
unknown cause (117 cases), which is likely to include
some patients with Pneumocystis carinii pneumonia (table
3). Weight loss of >10% body weight was a frequent prob-
lem and affected 383 (25.5%) patients (table 3).
Between 1996 and 2001 there was a continuous increase
in the total number of AIDS-defining disease episodes
occurring each year, due to the increase in the number of
patients being followed up. There was no significant
change in the overall proportion of AIDS-definingBMC Infectious Diseases 2004, 4:47 http://www.biomedcentral.com/1471-2334/4/47
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Table 1: The most frequent initial AIDS-defining conditions in 834 Singaporean patients.
Condition Median CD4 (IQR1) Confirmed Probable Total (%)
Pneumocystis carinii pneumonia 16.5 (9 – 40) 203 139 342 (35.7)
Mycobacterium tuberculosis 52 (18 – 110) 148 70 218 (22.7)
Herpes simplex, chronic mucocutaneous 25 (9 – 63) 26 45 71 (7.4)
Candidiasis, esophageal or tracheobronchial 21 (8.5 – 86) 25 41 66 (6.9)
Cytomegalovirus disease 25 (10 – 51) 28 12 40 (4.2)
Cryptococcosis, extrapulmonary 13 (6.5 – 39) 41 NA 41 (4.3)
Cytomegalovirus retinitis 15 (8 – 38.5) 0 37 37 (3.9)
Mycobacterium avium, disseminated 13 (5 – 26) 35 NA 35 (3.6)
Toxoplasmosis of the brain 29 (15 – 44) 1 31 32 (3.3)
Mycobacterium, species unidentified 31 (12 – 80) 0 16 16 (1.7)
Kaposi's sarcoma 46.5 (23.5 – 227.5) 8 4 12 (1.3)
Cryptosporidiosis, chronic intestinal 31 (4 – 56) 8 NA 8 (0.8)
Burkitt's lymphoma 34 (15.5 – 64) 8 NA 8 (0.8)
Wasting syndrome of HIV 36 (25 – 65) NA 6 6 (0.6)
Progressive multifocal leukoencephalopathy 42.5 (24.5 – 56.5) 2 3 5 (0.5)
Histoplasmosis, disseminated 22 (4 – 138) 5 NA 5 (0.5)
Other2 ----- 11 6 17 (1.8)
Total 27 (11 – 63) 549 410 959 (100)
1IQR = inter-quartile range. 2The category designated "other" includes conditions for which four cases or fewer were diagnosed. The number of 
initial AIDS-defining conditions is greater than the number of patients with AIDS because many patients presented with more than one condition. 
NA = not applicable.
Table 2: The most frequent conditions among 1742 overall category C episodes
Condition Confirmed Probable New Recurrent Total (%)
Pneumocystis carinii pneumonia 251 196 399 28 437 (25.1%)
Mycobacterium tuberculosis 194 89 263 20 283 (16.2%)
Cytomegalovirus retinitis 0 166 166 NA1 166 (9.5%)
Candidiasis, esophageal or tracheobronchial 40 96 129 7 136 (7.8%)
Herpes simplex, chronic mucocutaneous 59 84 133 10 143 (8.2%)
Mycobacterium avium, disseminated 141 NA 138 3 141 (8.2%)
Cytomegalovirus disease 79 35 112 2 114 (6.5%)
Cryptococcosis, extrapulmonary 84 NA 78 6 84 (4.8%)
Toxoplasmosis of the brain 2 61 57 6 63 (3.6%)
Mycobacterium, species unidentified 1 33 34 0 34 (2.0%)
Kaposi's sarcoma 17 6 23 0 23 (1.3%)
Cryptosporidiosis, chronic intestinal 19 NA 18 1 19 (1.1%)
Lymphoma, primary cerebral 10 10 20 0 20 (1.1%)
Wasting syndrome of HIV NA 16 16 0 16 (0.9%)
Encephalopathy, HIV-related NA 10 10 0 10 (0.6%)
Pneumonia, recurrent bacterial 9 NA 8 1 9 (0.5%)
Burkitt's lymphoma 9 NA 9 0 9 (0.5%)
Progressive multifocal leukoencephalopathy 2 5 7 0 7 (0.4%)
Histoplasmosis, disseminated 6 NA 6 0 6 (0.3%)
Mycobacterium scrofulaceum, disseminated 5 NA 5 0 5 (0.3%)
Other2 16 1 17 0 17 (1.0%)
1Following an initial diagnosis of cytomegalovirus retinitis, recurrences were not recorded as additional episodes of category C disease. 2The 
category designated "other" includes conditions for which four cases or fewer were diagnosed.BMC Infectious Diseases 2004, 4:47 http://www.biomedcentral.com/1471-2334/4/47
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episodes caused by infections. Pneumocystis carinii and M.
tuberculosis remained the two commonest causes. Between
1986 and 1995 they respectively accounted for 26.7% and
10.8% of all AIDS-defining disease episodes. During 2000
to 2001 the percentage of episodes caused by Pneumocystis
carinii was not significantly different at 26.3% (Yates' χ2 =
0.01, 2df, P = 0.94), but that due to M. tuberculosis had
increased to 18.0% (Yates' χ2 = 8.10, 2df, P = 0.004). There
was no significant change in the percentage of episodes
due to cytomegalovirus retinitis (9.7% between 1986 and
1995 and 8.5% during 2000 and 2001; Yates' χ2 = 0.25,
2df, P = 0.62) (table 4).
Discussion
Comparison of HIV-associated morbidity with other 
populations
In the SHOCS cohort the proportion of conditions which
were of infectious etiology remained very high through-
out the study period. The distribution of conditions was
similar to that seen in Western countries prior to the
introduction of anti-retroviral therapy [1]. However the
proportion of conditions caused by mycobacteria was
higher than in Europe [1,12]. In Bangkok the most com-
mon AIDS-defining conditions were infections. Between
1986 and 1993 the most frequent AIDS-defining illnesses
Table 3: Conditions which may have been undiagnosed category C illnesses and important non-category C conditions
Possible category C conditions New Recurrent Total
Pneumonia, cause unknown1 114 3 117
Non-Hodgkin's lymphoma, extracerebral2 2 502 5
Meningitis, cause unknown3 2 102 1
Dementia4 2 002 0
Cerebral lesion, cause unknown5 1 801 8
Non-category C conditions
Weight loss, >10% bodyweight 379 46 383
Pneumonia, bacterial 102 47 106
Salmonella septicemia 86 08 86
Penicillium marneffei, disseminated 5 1 6
1Some of these patients died before a diagnosis could be established and others recovered following a mixture of antibacterial and Pneumocystis 
treatments. Therefore the majority of these cases are likely to be due to bacteria or Pneumocystis carinii infections. 2Histology in these cases was not 
sufficiently specific to confirm a diagnosis of Burkitt's or immunoblastic lyphoma. 3These patients represent a diverse mixture of cases without a 
confirmed diagnosis, but they are believed to include mycobacterial, bacterial, viral and fungal infections. 4This excludes cases which fulfilled the 
diagnosis of HIV-related encephalopathy. 5Many of these cases died soon after diagnosis and are likely to include a large number of patients with 
toxoplasmosis of the brain. 6Recurrent weight loss indicates that weight was regained and subsequently lost again and not that 20% of body weight 
was lost. 7These cases of recurrence of bacterial pneumonia were not category C conditions as they occurred more than 12 months after the 
preceding case. 8Four cases of recurrent Salmonella septicaemia are included in the "other" category of table 3.
Table 4: Number of episodes per year for the 12 most frequent overall AIDS-defining conditions
Condition 1986–1995 1996–1999 2000–2001 Total
Pneumocystis carinii pneumonia 94 (26.7) 197 (23.6) 146 (26.3) 437 (25.1)
Mycobacterium tuberculosis 38 (10.8) 145 (17.4) 100 (18.0) 283 (16.2)
Cytomegalovirus retinitis 34 (9.7) 85 (10.2) 47 (8.5) 166 (9.5)
Candidiasis, esophageal or tracheobronchial 16 (4.5) 70 (8.4) 50 (9.0) 136 (7.8)
Herpes simplex, chronic mucocutaneous 27 (7.7) 71 (8.5) 45 (8.1) 143 (8.2)
Mycobacterium avium, disseminated 22 (6.3) 86 (10.3) 33 (5.9) 141 (8.1)
Cytomegalovirus disease 29 (8.2) 46 (5.5) 39 (7.0) 114 (6.5)
Cryptococcosis, extrapulmonary 19 (5.4) 34 (4.1) 31 (5.6) 84 (4.8)
Toxoplasmosis of the brain 19 (5.4) 24 (2.9) 20 (3.6) 63 (3.6)
Mycobacterium, species unidentified 7 (2.0) 14 (1.7) 13 (2.3) 34 (2.0)
Kaposi's sarcoma 15 (4.3) 6 (0.7) 2 (0.4) 23 (1.3)
Cryptosporidiosis, chronic intestinal 3 (0.9) 9 (1.1) 7 (1.3) 19 (1.1)
Total1 352 (100) 834 (100) 556 (100) 1742 (100)
This table shows the new and recurrent episodes combined. Figure in brackets are the percentages for each time period. 1Total also includes AIDS-
defining conditions other than the 12 most frequent.BMC Infectious Diseases 2004, 4:47 http://www.biomedcentral.com/1471-2334/4/47
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in Bangkok were extra-pulmonary tuberculosis (22.8%),
cryptococcal meningitis (10.9%) and Pneumocystis carinii
pneumonia (7%) [33]. Between 1993 and 1996 they were
extrapulmonary cryptococcosis (38.4%), tuberculosis
(37.4%), wasting syndrome (8.1%) and Pneumocystis cari-
nii pneumonia (4.8%) [36]. Pneumocystis carinii pneumo-
nia caused a much higher proportion of AIDS-defining
diseases in Singapore than in Bangkok and cryptococcal
meningitis occurred less frequently in Singapore.
Potential sources of bias
The SHOCS cohort provides data on the experience of
94.9% of Singaporean residents who have been diagnosed
with HIV since the epidemic began. There are good diag-
nostic facilities in Singapore and patients with HIV-related
illness receive extensive investigations. Therefore Singa-
pore offers an ideal location for collecting information on
the causes of morbidity and mortality in persons with HIV
in Asia. Medical record keeping is of a high standard in
our hospital and this allowed accurate diagnoses to be
assigned for AIDS-defining conditions which occurred
throughout the AIDS era. To ensure consistency, data was
extracted by carefully trained healthcare workers and diag-
noses were assigned using predefined criteria. All AIDS-
defining diagnoses and all causes of death were reviewed
by the same infectious diseases physician (RB). Follow-up
rates in our cohort are very high with only 5.8% of
patients lost to follow-up at 12 months and 9.3% after 3
years. The SHOCS cohort therefore provides a unique
source of information on HIV infection in an Asian coun-
try since the start of the epidemic.
In a retrospective study it is impossible to ensure that all
patients received a full series of investigations in order to
satisfy the study criteria for diagnosis of HIV-related con-
ditions. As a consequence the criteria for making a proba-
ble diagnosis are unavoidably biased against certain
conditions. For example if a patient undergoes a therapeu-
tic trial of tuberculosis treatment he or she can be given
the diagnosis of "probable Mycobacterium tuberculosis".
However if a patient receives a successful trial of treatment
for disseminated M. avium, the diagnosis is "probable
mycobacteriosis (species unidentified)".
Differences in physicians' awareness of the link between
HIV and opportunistic infections can influence diagnosis
rates. For example, the increase in the proportion of AIDS-
defining disease episodes caused by tuberculosis between
1986–1995 and 2000–2001 may have been due to greater
awareness of the link between HIV and tuberculosis. Diag-
nosis rates for M. avium and M. tuberculosis may also have
been affected by improvements in mycobacterial culture
techniques.
Conclusions
Despite the availability of anti-retroviral medication,
opportunistic infections remain a common problem
among HIV patients in Singapore. This may partly be
explained by the high proportion of Singaporean patients,
who present with advanced disease and very low CD4
counts. These patients often already have one or more
AIDS-defining opportunistic infections at first
presentation. Opportunistic infections may also occur
before adequate immune-reconstitution can occur when
HAART is commenced when the patient has a very low
CD4 count. Studies in the West have shown that AIDS-
defining illnesses occur more frequently among patients
who have a CD4 count below 50 when anti-retroviral
therapy is commenced than among those with higher
CD4 counts [37,38]. Immune-reconstitution may also be
impaired by difficulties in maintaining high levels of
adherence, sub-optimal treatment regimens and
unplanned treatment interruptions (due to adverse
effects, financial or logistical reasons).
The current reductions in the cost of anti-retroviral ther-
apy (Eg. due to generic manufacture) may enable high lev-
els of anti-retroviral use to be achieved in many Asian
countries. The experiences of the SHOCS cohort are likely
to be repeated throughout Asia. Our results suggest that
avoidable opportunistic infections may continue to occur
even when high levels of anti-retroviral use are achieved.
To reduce the burden of morbidity and mortality caused
by these infections, efforts must be made to diagnose HIV
infection earlier and to make the treatment of HIV and its
associated opportunistic infections more affordable.
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